Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress

AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag

Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

5 Cathie Wood Stocks to Buy in June

Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?

Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

Ionis to present at RBC Capital Markets Global Healthcare Conference

We Think Ionis Pharmaceuticals (NASDAQ:IONS) Can Stay On Top Of Its Debt

Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis reports first quarter financial results and recent business achievements

Ionis to host 2022 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Ionis to hold first quarter 2022 financial results webcast

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

Top Streaming News